We are analyzing https://link.springer.com/article/10.1007/s00345-009-0431-z.

Title:
Good-risk-advanced germ cell tumors: historical perspective and current standards of care | World Journal of Urology
Description:
Outcomes for patients with metastatic germ cell tumors have improved dramatically over the last 30 years with today’s cure rates approaching 80%. A critical contribution to the treatment of metastatic disease was the development of the universally accepted international germ cell cancer collaborative group (IGCCCG) outcome prediction model. With this system, patients are classified into good, intermediate, and poor-risk groups, each with a significantly different likelihood of cure. Not only are outcomes more favorable in the good-risk group, the intensity of treatment required to achieve these outcomes is also less. Therefore, the physician’s goal in treating good-risk patients is to minimize the short- and long-term therapy-related toxicities, while maintaining the excellent cure rates. Through well-conducted clinical trials, four cycles of etoposide + cisplatin (EP×4) and three cycles of bleomycin + etoposide + cisplatin (BEP×3) have emerged as the two optimal treatment regimens for good-risk patients. Cure rates with either regimen with or without surgery approximate to 90%. Attempts to further diminish the toxicity of either regimen have been unsuccessful due to the resulting reductions in efficacy. The authors discuss the trials which led to the establishment of EP×4 and BEP×3 as today’s treatment standards as well as the development of the IGCCCG prognostic model.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

google, scholar, pubmed, cancer, article, germ, cell, cas, oncol, testicular, clin, patients, tumors, bleomycin, chemotherapy, trial, research, etoposide, metastatic, treatment, cisplatin, group, nonseminomatous, prognostic, bosl, randomized, motzer, goodrisk, tumours, disseminated, access, study, germcell, privacy, cookies, content, journal, feldman, disease, longterm, versus, tumor, bajorin, einhorn, medical, van, goodprognosis, wit, analysis, european,

Topics {✒️}

etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin good-prognosis germ-cell tumours long-term therapy-related toxicities disseminated germ-cell tumors germ-cell tumours germ cell tumours month download article/chapter good-risk group germ cell tumors germ-cell tumors good-prognosis testicular nonseminoma treating good-risk patients poor-risk groups medical research council life-threatening acute complications �good-risk’ metastatic bleomycin combination chemotherapy genito-urinary group article world journal full article pdf combination chemotherapy good-risk patients metastatic testicular cancer long-term risk loehrer pj advanced metastatic seminoma disseminated testicular cancer maintenance therapy van veldhuisen dj metastatic disease standard chemotherapy regimens privacy choices/manage cookies related subjects post-chemotherapy resection testicular tumours care review published cisplatin versus etoposide sidney kimmel center long-term complication therapy effective chemotherapy regimen optimal chemotherapy regimen long-term survivors de mulder ph adult male patients european economic area check access huddart ra getug t93 bp higher acute morbidity

Questions {❓}

Mosharafa AA, Foster RS, Leibovich BC, Bihrle R, Johnson C, Donohue JP (2003) Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Good-risk-advanced germ cell tumors: historical perspective and current standards of care
         description:Outcomes for patients with metastatic germ cell tumors have improved dramatically over the last 30 years with today’s cure rates approaching 80%. A critical contribution to the treatment of metastatic disease was the development of the universally accepted international germ cell cancer collaborative group (IGCCCG) outcome prediction model. With this system, patients are classified into good, intermediate, and poor-risk groups, each with a significantly different likelihood of cure. Not only are outcomes more favorable in the good-risk group, the intensity of treatment required to achieve these outcomes is also less. Therefore, the physician’s goal in treating good-risk patients is to minimize the short- and long-term therapy-related toxicities, while maintaining the excellent cure rates. Through well-conducted clinical trials, four cycles of etoposide + cisplatin (EP×4) and three cycles of bleomycin + etoposide + cisplatin (BEP×3) have emerged as the two optimal treatment regimens for good-risk patients. Cure rates with either regimen with or without surgery approximate to 90%. Attempts to further diminish the toxicity of either regimen have been unsuccessful due to the resulting reductions in efficacy. The authors discuss the trials which led to the establishment of EP×4 and BEP×3 as today’s treatment standards as well as the development of the IGCCCG prognostic model.
         datePublished:2009-06-10T00:00:00Z
         dateModified:2009-06-10T00:00:00Z
         pageStart:463
         pageEnd:470
         sameAs:https://doi.org/10.1007/s00345-009-0431-z
         keywords:
            Germ cell tumors
            Prognostic models
            Review
            Chemotherapy
            Good-risk disease
            Urology
            Nephrology
            Oncology
         image:
         isPartOf:
            name:World Journal of Urology
            issn:
               1433-8726
               0724-4983
            volumeNumber:27
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Darren R. Feldman
               affiliation:
                     name:Memorial Sloan-Kettering Cancer Center
                     address:
                        name:Genitourinary Oncology Service Division of Solid Tumors, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Robert J. Motzer
               affiliation:
                     name:Memorial Sloan-Kettering Cancer Center
                     address:
                        name:Genitourinary Oncology Service Division of Solid Tumors, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Good-risk-advanced germ cell tumors: historical perspective and current standards of care
      description:Outcomes for patients with metastatic germ cell tumors have improved dramatically over the last 30 years with today’s cure rates approaching 80%. A critical contribution to the treatment of metastatic disease was the development of the universally accepted international germ cell cancer collaborative group (IGCCCG) outcome prediction model. With this system, patients are classified into good, intermediate, and poor-risk groups, each with a significantly different likelihood of cure. Not only are outcomes more favorable in the good-risk group, the intensity of treatment required to achieve these outcomes is also less. Therefore, the physician’s goal in treating good-risk patients is to minimize the short- and long-term therapy-related toxicities, while maintaining the excellent cure rates. Through well-conducted clinical trials, four cycles of etoposide + cisplatin (EP×4) and three cycles of bleomycin + etoposide + cisplatin (BEP×3) have emerged as the two optimal treatment regimens for good-risk patients. Cure rates with either regimen with or without surgery approximate to 90%. Attempts to further diminish the toxicity of either regimen have been unsuccessful due to the resulting reductions in efficacy. The authors discuss the trials which led to the establishment of EP×4 and BEP×3 as today’s treatment standards as well as the development of the IGCCCG prognostic model.
      datePublished:2009-06-10T00:00:00Z
      dateModified:2009-06-10T00:00:00Z
      pageStart:463
      pageEnd:470
      sameAs:https://doi.org/10.1007/s00345-009-0431-z
      keywords:
         Germ cell tumors
         Prognostic models
         Review
         Chemotherapy
         Good-risk disease
         Urology
         Nephrology
         Oncology
      image:
      isPartOf:
         name:World Journal of Urology
         issn:
            1433-8726
            0724-4983
         volumeNumber:27
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Darren R. Feldman
            affiliation:
                  name:Memorial Sloan-Kettering Cancer Center
                  address:
                     name:Genitourinary Oncology Service Division of Solid Tumors, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Robert J. Motzer
            affiliation:
                  name:Memorial Sloan-Kettering Cancer Center
                  address:
                     name:Genitourinary Oncology Service Division of Solid Tumors, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:World Journal of Urology
      issn:
         1433-8726
         0724-4983
      volumeNumber:27
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Memorial Sloan-Kettering Cancer Center
      address:
         name:Genitourinary Oncology Service Division of Solid Tumors, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA
         type:PostalAddress
      name:Memorial Sloan-Kettering Cancer Center
      address:
         name:Genitourinary Oncology Service Division of Solid Tumors, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Darren R. Feldman
      affiliation:
            name:Memorial Sloan-Kettering Cancer Center
            address:
               name:Genitourinary Oncology Service Division of Solid Tumors, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Robert J. Motzer
      affiliation:
            name:Memorial Sloan-Kettering Cancer Center
            address:
               name:Genitourinary Oncology Service Division of Solid Tumors, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Genitourinary Oncology Service Division of Solid Tumors, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA
      name:Genitourinary Oncology Service Division of Solid Tumors, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(127)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.34s.

LINK . SPRINGER . COM {}